Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 401–500 of 682
Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides
Takano, Y., Kasai, K., Takagishi, Y., Kikumori, T., Imai, T., Murata, Y., & Hayashi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133812 · Cited by 13
“Aberrant α-cell proliferation and dysregulated glucagon secretion are postulated to play important roles in the pathogenesis of diabetes mellitus [4], however, the regulatory mechanisms that control islet α-cell mass are not well understood [5, 6].”
BackgroundAhrén, B., Yamada, Y., & Seino, Y. (2021) · Peptides · doi:10.1016/j.peptides.2020.170434 · Cited by 12
A computational systems analysis of factors regulating α cell glucagon secretion
Fridlyand, L. E., & Philipson, L. H. (2012) · Islets · doi:10.4161/isl.22193 · Cited by 12
“6, 19 and 20) has increased the importance of understanding how electrical activity induced by metabolism of sugar and other agonists is established and how it is altered in various pathological states.”
BackgroundInfluentialPreproglucagon Products and Their Respective Roles Regulating Insulin Secretion
Bethea, M. M., Bozadjieva-Kramer, N., & Sandoval, D. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab150 · Cited by 12
Eriksson, J. W., Emad, R. A., Lundqvist, M., Abrahamsson, N., & Kjellsson, M. C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0506 · Cited by 12
Lajara, R., Aguilar, R. B., Hehnke, U., Woerle, H., & von Eynatten, M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.020 · Cited by 12
Regulation of α‐cell glucagon secretion: The role of second messengers
Acreman, S., & Zhang, Q. (2022) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.06.001 · Cited by 14
The heterogeneity of type 1 diabetes: From immunopathology to immune intervention
Infante, M., Alejandro, R., Fabbri, A., & Ricordi, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824466-1.00001-7 · Cited by 12
Peng, H., Hou, M. L., Wu, Z., Wang, J., Zhou, M., Zhuang, X., Xing, J., Tao, Q., Huang, L., Zhou, F., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11503 · Cited by 12
“At the cellular level, metformin is thought to counteract the insulin signaling pathway by reducing cyclic adenosine monophosphate (cAMP) production or activating AMP-activated protein kinase (AMPK), thereby disrupting the hepatic glucose metabolic process [7, 16, 17, 18, 19, 20].”
BackgroundGoode, R. A., Hum, J. M., & Kalwat, M. A. (2022) · Endocrinology · doi:10.1210/endocr/bqac193 · Cited by 13
Glucagon secretion is increased in patients with Type 2 diabetic nephropathy
Wang, X., Yang, J., Chang, B., Shan, C., Xu, Y., Zheng, M., Wang, Y., Ren, H., & Chen, L. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.020 · Cited by 12
“Diabetes mellitus is a dual hormone disease, and its pathogenesis includes the dysfunction of islet alpha cell and beta cell (Lee et al., 2012; Unger & Cherrington, 2012).”
Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice
McShane, L. M., Irwin, N., O’Flynn, D., Franklin, Z. J., Hewage, C. M., & O'Harte, F. P. M. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0463 · Cited by 12
An optical method to evaluate both mass and functional competence of pancreatic α- and β-cells
Wang, Y., Han, C., Zhu, W., Wu, Z., Liu, Y., & Chen, L. (2016) · Journal of Cell Science · doi:10.1242/jcs.184523 · Cited by 12
“Increases in α-cell mass and glucagon hypersecretion during the pathogenesis of type 2 diabetes have also been reported (Unger and Cherrington, 2012).”
BackgroundHyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?
Barbetti, F., Colombo, C., Haataja, L., CRAS-MÉNEUR, C. M. H., Bernardini, S., & Arvan, P. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0029-5 · Cited by 14
“Hyperglucagonemia, which is believed to derive mainly from a loss of insulin-mediated intra-islet suppression of glucagon production [24, 25, 36], is increasingly recognized as an important cause of hyperglycemia [26], and we have reported hyperglucagonemia as a phenotypic feature in MIDY patients [11].”
BackgroundModelling the effects of glucagon during glucose tolerance testing
Kelly, R. A., Fitches, M. J., Webb, S. D., Pop, S. R., & Chidlow, S. J. (2019) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-019-0115-3 · Cited by 11
Chlorogenic Acid Inhibits Ceramide Accumulation to Restrain Hepatic Glucagon Response
Xiao, N., Zhang, T., Han, M., Tian, D., Liu, J., Li, S., Yang, L., & Pan, G. (2023) · Nutrients · doi:10.3390/nu15143173 · Cited by 12
Wang, D., Wei, T., Cui, X., Li, X., Jiang, Y., Yin, D., Liao, X., Li, F., Li, J., Wu, Q., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156042 · Cited by 12
A famsin-glucagon axis mediates glucose homeostasis
Long, A., Wang, Y., Guo, Y., Hong, J., Ning, G., Meng, Z., Wang, J., & Wang, Y. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.008 · Cited by 12
Kang, R. B., Varela, M., Oh, E., Lee, J. E., Zhang, T., Karaköse, E., Stewart, A. F., Scott, D. K., Thurmond, D. C., García-Ocaña, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62670-5 · Cited by 12
“Data were normalized to the respective protein content.”
InfluentialMetabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
“Over time, these adaptations may lead to progressive metabolic dysfunction and an increased risk of type 2 diabetes [69].”
Hyperglycemia in Turner syndrome: Impact, mechanisms, and areas for future research
Mitsch, C., Alexandrou, E., Norris, A. W., & Pinnaro, C. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1116889 · Cited by 16
Bessho, M., Murase‐Mishiba, Y., Tsutsumi, C., Haseda, F., Imagawa, A., Terasaki, J., & Hanafusa, T. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.003 · Cited by 12
“Because glucagon reacts paradoxically to hyperglycemia when it is not under paracrine control by endogenous insulin [7], it is suggested that this glucagon release from the preserved alphacell secretion may have redundant function and exaggerate the blood glucose swings.”
BackgroundGupta, A., Al-Aubaidy, H. A., & Mohammed, B. I. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.03.013 · Cited by 12
Hypoglycemia unawareness prevention: Targeting glucagon production
Samson, W. K., Stein, L. M., Elrick, M. M., Salvatori, A. S., Kolar, G. R., Corbett, J. A., & Yosten, G. L. C. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.04.012 · Cited by 11
“When blood glucose levels fall below 80mg/dl, the stimulus for insulin secretion from the pancreatic beta cell is withdrawn [3,22] and the combination of decreased blood glucose and insulin levels removes the brake on the alpha cell leading to glucagon secretion and the recruitment of endogenous fuel stores.”
Huang, W. Q., Guo, J. H., Yuan, C., Cui, Y. G., Diao, F., Yu, M., Liu, J. Y., Ruan, Y. C., & Chan, H. C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00835 · Cited by 11
“Its dysregulation is considered to underlie insulin deficiency, resulting in glucose metabolic disorders, such as diabetes, hypoglycemia (Cryer, 2002; Unger and Cherrington, 2012).”
BackgroundCellular autophagy in α cells plays a role in the maintenance of islet architecture
Himuro, M., Miyatsuka, T., Suzuki, L., Miura, M., Katahira, T., Goto, H., Nishida, Y., Sasaki, S., Koike, M., Shiota, C., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00075 · Cited by 13
Galsgaard, K. D., Pedersen, J., Kjeldsen, S. A. S., Winther‐Sørensen, M., Stojanovska, E., Vilstrup, H., Ørskov, C., Albrechtsen, N. J. W., & Holst, J. J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00294.2019 · Cited by 11
Xu, S.-Y., Ke-Li, Zhang, Z., Liu, C., Guo, Q., Lu, B., Gu, P., & Shao, J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108684 · Cited by 11
Espinoza, L., Fedorchak, S., & Boychuk, C. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.624595 · Cited by 11
Etiology and Pathogenesis of Diabetes Mellitus in Children and Adolescents
Yau, M., Maclaren, N. K., & Sperling, M. A. (2021) · Europe PMC (PubMed Central) · Cited by 22
Glucagon receptor blockage inhibits β-cell dedifferentiation through FoxO1
Wang, K., Cui, X., Li, F., Li, X., Wei, T., Liu, J., Fu, W., Yang, J., Hong, T., & Wei, R. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2022 · Cited by 12
Chang, Y.-H., Katoh, M., Abdellatif, A. M., Xiafukaiti, G., Ibrahim, E. A. E., Ojima, M., Mizuno, S., Kuno, A., & Takahashi, S. (2019) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.19-0105 · Cited by 10
“However, increasing evidence suggests that dysfunction of α-cells and dysregulated glucagon secretion contribute to dysglycemia in both type 1 and type 2 diabetes via exacerbating the chronic hyperglycemia caused by insulin deficiency [13, 42, 43].”
BackgroundXiao, N., Xu, Y., Zhang, X., Li, H., Zhang, S., Xiao, A., Yu, J., Yang, M., Lv, F., Zhang, M., et al. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2021.792810 · Cited by 10
“Diabetes is a group of metabolic diseases characterized by hyperglycemia, which is caused by impaired peripheral glucose uptake and elevated hepatic glucose production (Unger and Cherrington, 2012; Jiang et al., 2021).”
BackgroundInfante, M., & Ricordi, C. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168645 · Cited by 11
Rix, I., Johansen, M. L., Lund, A., Suppli, M. P., Chabanova, E., van Hall, G., Holst, J. J., Albrechtsen, N. J. W., Kistorp, C., & Knop, F. K. (2023) · Endocrine Connections · doi:10.1530/ec-23-0161 · Cited by 15
Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function
Omar, B. A., Sörhede‐Winzell, M., & Åhrén, B. (2014) · Metabolism · doi:10.1016/j.metabol.2014.09.004 · Cited by 11
“pression of the glucagon receptor in T2D may have complex influences involving both augmented beta-cell secretion and impaired beta-cell function [9].”
BackgroundInfluentialGlucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Glucagon infusion alters the hyperpolarized 13C‐urea renal hemodynamic signature
Qi, H., Mariager, C. Ø., Nielsen, P. M., Schroeder, M., Lindhardt, J. L., Nørregaard, R., Klein, J. D., Sands, J. M., & Laustsen, C. (2018) · NMR in Biomedicine · doi:10.1002/nbm.4028 · Cited by 10
Singha, A. K., Palavicini, J. P., Pan, M., Farmer, S., Sandoval, D. A., Han, X., & Fujikawa, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.588447 · Cited by 10
Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
Modrzynska, J., Klein, C. F., Iversen, K. K., Bundgaard, H., Hartmann, B., Mose, M., Rittig, N. F., Møller, N., Holst, J. J., & Albrechtsen, N. J. W. (2021) · Endocrine Connections · doi:10.1530/ec-20-0590 · Cited by 10
Protein kinase C-δ signaling regulates glucagon secretion from pancreatic islets
Yamamoto, K., Mizuguchi, H., Tokashiki, N., Kobayashi, M., Tamaki, M., Sato, Y., Fukui, H., & Yamauchi, A. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.122 · Cited by 10
Katahira, T., Kanazawa, A., Shinohara, M., Koshibu, M., Kaga, H., Mita, T., Tosaka, Y., Komiya, K., Miyatsuka, T., Ikeda, F., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00142 · Cited by 10
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Kim, I., & Yun, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091098 · Cited by 9
“In diabetes, inappropriate hyperglucagonemia contributes to fasting and postprandial hyperglycemia [64].”
Ketosis-Prone Atypical Diabetes: Glucagon Is There, Too
Lefèbvre, P. (2012) · Diabetes Care · doi:10.2337/dc12-1696 · Cited by 9
“These observations should be discussed in the frame of the recently developed concept that diabetes should be seen as a paracrinopathy of the islets of Langerhans, in which hyperglucagonemia would result from intraislet insulin paracrine deficiency (9,10), while glucagon should be reconsidered as a key factor in the p…”
BackgroundMirasierra, M., & Vallejo, M. (2016) · Diabetologia · doi:10.1007/s00125-015-3849-4 · Cited by 9
“Dysfunctional glucagon hypersecretion contributing to hyperglycaemia has been recognised as an important factor in this disease [3, 4], suggesting the existence of impaired glucose-dependent inhibitory mechanisms affecting glucagon gene expression and hormone secretion.”
BackgroundThe relationship between glucose and the liver-alpha cell axis – A systematic review
Pixner, T., Stummer, N., Schneider, A.-M., Lukas, A., Gramlinger, K., Julian, V., Thivel, D., Mörwald, K., Mangge, H., Dalus, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061682 · Cited by 11
Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus
Hoque, M., Ali, S., & Hoda, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.091 · Cited by 9
Zhang, J., Schaefer, S. M., Kabisch, S., Csanalosi, M., Schuppelius, B., Kemper, M., Markova, M., Meyer, N. M. T., Pivovarova‐Ramich, O., Keyhani‐Nejad, F., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.011 · Cited by 10
Glucagon's yin and yang effects on hepatic glucose production
Edgerton, D. S., & Cherrington, A. D. (2013) · Nature Medicine · doi:10.1038/nm.3202 · Cited by 10
Self-citationPeptide Signaling in Taste Transduction
Takai, S., Yoshida, R., Shigemura, N., & Ninomiya, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801694-7.00017-2 · Cited by 10
Asadi, F., & Dhanvantari, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00792 · Cited by 12
Glucagon receptor signalling – backwards and forwards
Wu, T., Rayner, C. K., Marathe, C. S., Jones, K. L., & Horowitz, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1428306 · Cited by 10
Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations
Hayashi, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13110 · Cited by 9
“A glucagonocentric view of diabetes mellitus was proposed in 2012 by Unger et al.2 that might have further reinforced the concept of glucagon as a hyperglycemic substance and, thereby, an aggravating factor of diabetes mellitus.”
BackgroundYip, L., Alkhataybeh, R., Taylor, C., Fuhlbrigge, R., & Fathman, C. G. (2022) · Diabetes · doi:10.2337/db21-0948 · Cited by 8
Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease
Maruszczak, K., Radzikowski, K., Schütz, S., Mangge, H., Bergsten, P., Forslund, A. H., Manell, H., Pixner, T., Ahlström, H. K., Kullberg, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004128 · Cited by 9
“Increased fasting levels of glucagon can be found in T2DM patients and in subjects with obesity and normal glucose tolerance (11, 12).”
BackgroundZBED3 exacerbates hyperglycemia by promoting hepatic gluconeogenesis through CREB signaling
Luo, Y., Ruan, C.-S., Zhao, F.-Z., Yang, M., Cui, W., Cheng, X., Luo, X.-H., Zhang, X.-X., & Zhang, C. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156049 · Cited by 8
Recent advances in understanding/managing type 2 diabetes mellitus
Aschner, P. J. (2017) · F1000Research · doi:10.12688/f1000research.11192.1 · Cited by 9
Zhao, W., Feng, X., Liu, B., Xian, J.-C., & Zhang, N. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01041 · Cited by 9
“Several lines of evidence demonstrate that enhanced hepatic glucagon response is responsible for hyperglycemia during fasting (Unger and Cherrington, 2012).”
BackgroundGao, J., Li, H., Xu, H., Liu, Y., Cai, M., Shi, Y. C., Zhang, J., & Wang, H. (2023) · iScience · doi:10.1016/j.isci.2023.105967 · Cited by 8
“As inhibition of GCGR activity can reduce excess glucose production, GCGR has been viewed as a crucial drug target for treatment of type 2 diabetes.(11) Since the early 1980s, GCGR antagonists have been reported in animalmodels,(12,13) for clinical use, and recently also been confirmed in patients with type 2 diabetes.”
BackgroundPhysiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
“to propose a glucagonocentric view of diabetes in which glucagon is considered as the sine qua none condition of diabetes (Unger and Cherrington 2012).”
BackgroundInfluentialSingh‐Franco, D. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1004311 · Cited by 12
“Glucagon is a potent stimulator of hepatic glucose production in response to hypoglycemia; however, in individuals who are glucose intolerant or have T2DM, glucagon secretion is dysregulated, contributing to hyperglycemia [26].”
BackgroundBedinger, D., Kieffer, D. A., Goldfine, I. D., Roell, M. K., & Adams, S. H. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25168 · Cited by 8
Nuevas proyecciones fisiológicas, patológicas y terapéuticas de la leptina
Goldenberg, D., Santos, J. L., Hodgson, M. I., & Cortés, V. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000600008 · Cited by 17
Li, H., Parry, J. W., Weeda, S. M., Ren, S., Castonguay, T. W., & Guo, T. L. (2016) · Food and Nutrition Sciences · doi:10.4236/fns.2016.77066 · Cited by 9
“Disruption of the equilibration by augmented secretion of glucagon and decreased secretion of insulin typically promotes commenced postprandial hyperglycemia [30] [31].”
BackgroundDolo, P. R., Shao, Y., Li, C., Zhu, X., Yao, L., & Wang, H. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03776-w · Cited by 8
Bridging the variant-to-function gap in type 2 diabetes: advances and challenges
Maynard, A. G., Bhardwaj, R., Jones, T. R., & Claussnitzer, M. (2025) · Diabetologia · doi:10.1007/s00125-025-06600-6 · Cited by 10
“…reflecting ectopic lipid overflow and impaired lipid storage [5]; (4) chronic low-grade inflammation in peripheral tissues (e.g. adipose, pancreatic islets) associated with increased immune cell infiltration and inflammatory cytokine secretion [6]; and (5) hyperglucagonaemia [7].”
The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia
Kim, M.-K., Lee, E. J., Shin, H., Jung, H. S., Kim, T. K., Kim, T. N., Kwon, M. J., Lee, S. H., Rhee, B. D., & Park, J. H. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0659-1 · Cited by 7
Ruiz-Pino, A., Goncalves-Ramírez, A., Jiménez-Palomares, M., Merino, B., Castellano-Muñoz, M., Vettorazzi, J. F., Rafacho, A., Marroquí, L., Nadal, Á., Alonso‐Magdalena, P., et al. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03045-5 · Cited by 11
“Nevertheless, despite comparable fasting glucagon levels between controls and db/db animals, the latter also presented marked hyperinsulinemia and hyperglycemia, pointing to the notion of relative hyperglucagonemia [8, 54, 57].”
InfluentialProtein Kinase C (Pkc)-δ Mediates Arginine-Induced Glucagon Secretion in Pancreatic α-Cells
Honzawa, N., Fujimoto, K., Kobayashi, M., Kohno, D., Kikuchi, O., Yokota‐Hashimoto, H., Wada, E., Ikeuchi, Y., Tabei, Y., Dorn, G. W., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074003 · Cited by 7
“This indicates that the presence of glucagon is more critical for glucose intolerance than insulin deficiency [4].”
BackgroundKang, Q., Zheng, J., Jia, J., Xü, Y., Bai, X., Chen, X., Zhang, X.-K., Wong, F. S., Zhang, C., & Li, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102665 · Cited by 7
“083; Column factor (glucose treatment): F (1, 26) = 12.”
BackgroundInfluentialFurió-Novejarque, C., Sanz, R., Ritschel, T. K. S., Reenberg, A. T., Ranjan, A. G., Nørgaard, K., Díez, J.-L., Jørgensen, J. B., & Bondía, J. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106605 · Cited by 7
Coate, K. C., Ramnanan, C. J., Smith, M., Winnick, J. J., Kraft, G., Irimia-Dominguez, J., Farmer, B., Donahue, E. P., Roach, P. J., Cherrington, A. D., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00316.2023 · Cited by 7
“Glucagon also plays a fundamental role in 50 the pathogenesis of diabetes; increasing fasting glucose production and impairing hepatic glucose 51 uptake (13, 46, 60, 61).”
BackgroundSelf-citationSisnande, T., Brum, F. L., Matias, D. O., Ribeiro, F. D. S., Beninatto, T. M., Mohana‐Borges, R., de Magalhães, M. T. Q., & Lima, L. M. T. R. (2024) · Analytical Biochemistry · doi:10.1016/j.ab.2024.115570 · Cited by 7
ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia
Kang, Q., Jia, J., Dean, E. D., Yuan, H., Dai, C., Li, Z., Jiang, F., Zhang, X.-K., Powers, A. C., Chen, W., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107499 · Cited by 7
“GCGR antagonism is thus proposed as a diabetes treatment (5, 6).”
Backgroundβ‐Cell mass and function in human type 2 diabetes
Marchetti, P., & Ferrannini, E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch24 · Cited by 13
Chowdhury, S., Grimm, L., Gong, Y. J. K., Wang, B., Li, B., Srikant, C. B., Gao, Z., & Liu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136656 · Cited by 8
“This would be consistent with 11β-HSD1-/- mice showing increased insulin but decreased glucose levels [30], and with the emerging importance of glucagon and α-cells in the etiology of diabetes mellitus [36].”
BackgroundÅhrén, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30002-7 · Cited by 7
“In fact, as recently discussed [10], α-cells in the islets are normally exposed to levels of insulin that are at least 100 times higher than the insulin levels reached in skeletal muscle, whereas injected insulin provides similar insulin concentrations in all tissues.”
BackgroundXu, Y., & Tong, Q. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.027 · Cited by 7
Meek, T. H., Matsen, M. E., Faber, C. L., Samstag, C. L., Damian, V. M., Hồng, N. T., Scarlett, J. M., Flak, J. N., Myers, M. G., & Morton, G. J. (2018) · Endocrinology · doi:10.1210/en.2017-03199 · Cited by 7
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes
Sjöholm, Å. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939679 · Cited by 7
“reasons not an ideal way to treat T1D as both fasting and prandial hyperglucagonemia is affected only partially and patients already overweight risk further weight gain [3,4].”
BackgroundAsadi, F., Andrade, J. A. F., Gillies, R., Lee, K., Dhanvantari, S., Hardy, D. B., & Arany, E. J. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.06.009 · Cited by 7
Hormone glucagon: electrooxidation and determination at carbon nanotubes
Karra, S., Griffith, W. P., Kennedy, R. T., & Górski, W. (2016) · The Analyst · doi:10.1039/c5an02636a · Cited by 7
Dash, S., Xiao, C., Stahel, P., Koulajian, K., Giacca, A., & Lewis, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13069 · Cited by 7
“Glucagon has multiple metabolic effects, including increasing hepatic glucose output and promoting lipolysis.(1,2) I.”
BackgroundHughson, B. N. (2021) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2021.104339 · Cited by 7
Conroy, R., Febres, G., McMahon, D. J., Thorner, M. O., Gaylinn, B. D., Conwell, I. M., Aronne, L. J., & Körner, J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/120286 · Cited by 7
“However, this effect was observed only transiently in adult rats [37].”
BackgroundRole of cAMP in Double Switch of Glucagon Secretion
Zmazek, J., Grubelnik, V., Markovič, R., & Marhl, M. (2021) · Cells · doi:10.3390/cells10040896 · Cited by 8
Tamarit‐Rodriguez, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116052 · Cited by 6
“There is widespread agreement that blood glucagon levels are increased in diabetic patients despite the large increase in their blood glucose values [69].”
BackgroundNormal-weight Obesity: A Hidden Pandemic
Anoop, S., & Kapoor, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_26 · Cited by 7
Shigeno, R., Horie, I., Miwa, M., Ito, A., Haraguchi, A., Natsuda, S., Akazawa, S., Nagata, A., Hasegawa, Y., Miura, S., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0795 · Cited by 8
“In contrast, a para‐ doxical increase in glucagon secretion after glucose consumption occurs in patients with T2DM [22] and also in those with GDM [23].”
BackgroundIn vivo evidence for unidentified leptin-induced circulating factors that control white fat mass
Harris, R. B. S. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00335.2015 · Cited by 6
“Leptin is known to influence the release of other hormones, such as corticosterone (22) and glucagon (44), but the half-life of these proteins is short and they are unlikely to exchange between parabionts in significant amounts.”
BackgroundLau, J., Grapengiesser, E., & Hellman, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4930741 · Cited by 6
“Accordingly, the reduction of islet mass in diabetes results in a proportionally larger decrease of glucagon-producing α-cells than of βand δ-cells, a situation supposed to counteract hyperglycemia [26].”
BackgroundHorie, I., Haraguchi, A., Sako, A., Akeshima, J., Niri, T., Shigeno, R., Ito, A., Nozaki, A., Natsuda, S., Akazawa, S., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.08.015 · Cited by 6
Nakagawa, T., Nagai, Y., Yamamoto, Y. L., Miyachi, A., Hamajima, H., Mieno, E., Takahashi, M., Inoue, E., & Tanaka, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107892 · Cited by 8
Alpha Cell Stimulus-Secretion Coupling and Intercellular Interactions in Health and Type 2 Diabetes
Pohorec, V., Zadravec, N., Turk, M., Dolenšek, J., & Stožer, A. (2023) · Acta Medico-Biotechnica · doi:10.18690/actabiomed.246 · Cited by 9
Wang, H.-Y., Shen, Y., Nie, W., Tu, W., Huang, S., & Wu, X. (2024) · Phytochemistry · doi:10.1016/j.phytochem.2024.114364 · Cited by 5
Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk
Bao, K., Berger, J., Na, E., Su, Q., Halász, G., Sleeman, M. W., & Okamoto, H. (2025) · Diabetes · doi:10.2337/db24-0958 · Cited by 4
Velázquez‐Villegas, L. A., Tovar‐Palacio, C., Palacios‐González, B., Torres, N., Tovar, A. R., & Díaz‐Villaseñor, A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700116 · Cited by 5
Liu, X., Kong, F., Xiao, N., Li, X., Zhang, M., Lv, F., Liu, X., Kong, X., Bi, J., Lu, X., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1099103 · Cited by 5
“During fasting, hepatic gluconeogenesis is the primary source of glucagon-mediated endogenous glucose production (Unger and Cherrington, 2012).”
BackgroundA liquid chromatography tandem mass spectrometry method for plasma glucagon
Nguyen, V. L., Tuckwell, P., Ireland, A., & Fitzpatrick, M. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115229 · Cited by 5
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.